Management strategies for major depressive episodes as a function of initial response to an SSRI or SNRI antidepressant: Results of the ORACLE survey;Stratégie de prise en charge d'un EDM en fonction de la réponse précoce à un antidépresseur IRS ou IRSNA: Résultats de l'enquête ORACLE

Encephale

Volumn 31, Issue 6 I, 2005, Pages 698-704

  Spadone, C ^a   Sylvestre, M ^b   Chiarelli, P ^b   Richard Berthe, C ^c  

^a SAINT LOUIS HOSPITAL   (France)

^b GSK ^*

^c GSK Peter Merian Strasse   (Switzerland)

Author keywords

Antidepressant; Depression; Early respons

Indexed keywords

SEROTONIN UPTAKE INHIBITOR; ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; DATA ANALYSIS; DISEASE SEVERITY; HAMILTON SCALE; HEALTH SURVEY; HUMAN; MAJOR DEPRESSION; MEDICAL PRACTICE; MULTIVARIATE ANALYSIS; PATIENT SATISFACTION; PHYSICIAN; PSYCHOMETRY; REMISSION; TREATMENT OUTCOME; ADULT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; MALE; QUESTIONNAIRE;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; MALE; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS;

EID: 33645464784     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0013-7006(05)82428-5     Document Type: Article

References (18)

1. AFSSAPS. Bon usage des antidépresseurs. Mise au point (avril 2005).
2. ANAES. Traitement de l'EDM isolé de l'adulte en ambulatoire. Recommandations (mai 2002).
3. BECH P et al. Citalopram dose-response. Psychopharmacol (Berl) 2002 ; 163 (1) : 20-5.
4. CORRUBLE E, GUELFI JD. Is there a relationship between clinical efficacy and antidepressant dosage in major depression ? Encephale 1999 ; 25 (Spec 2) : 39-43.
5. DORNSEIF BE et al. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull 1989 ; 25 : 71-9.
6. FAVA GA et al. Residual symptoms in depression : an emerging therapeutic target. Prog Neuropsychopharmacol Biol Psychiatry 2002 ; 26 (6) : 1019-27.
7. FRANCHINI L et al. Dose-response efficacy of paroxetine in preventing depressive recurrences : a randomised double-blind study. J Clin Psychiatry 1998 ; 59 (5) : 229-32.
8. KELSEY JE. Dose-response relationship with venlafexine. J Clin Psychopharmacol 1996 ; 16 (3, Suppl 2) : 21S-26S.
9. LECRUBIER et al. Modules du MINI. Version 5.00.
10. LICHT RV, QVITZAU S. Treatment strategies in patients with major depression non responding to first line sertraline treatment. Psychopharmacol (Berl) 2002 ; 161 (2) : 143-51.
11. NIERENBERG AA et al. Early non-response to fluoxetine as a predictor of poor 8-week outcome. Psychiatry 1995 ; 152 (10) : 1500-3.
12. PAYKEL ES. Achieving gain beyond response. Acta Psychiatr Scand Suppl 2002 (415) : 12-8.
13. PAYKEL ES. Remission and residual symptomatology in major depression. Psychopathology 1998 ; 31 (1) : 5-14.
14. PAYKEL ES et al. Residual symptoms after partial remission : an important outcome in depression. Psychol Med 1995 ; 25 (6) : 1171-80.
15. RAMANA R et al. Remission and residual symptomatology in major depression. Psychopathology 1998 ; 31 (1) : 5-14.
16. SCHWEITZER E et al. The antidepressant effect of sertraline is not enhanced by dose titration : results from an outpatient clinical trial. Int Clin Psychopharmacol 2001 ; 16 (3) : 137-43.
17. SHEEHAN DV et al. The Mini International Neuropsychiatric Interview (MINI) : the development and validation of a structured diagnostic interview for DSM IV and ICD 10. J Clin Psychiatry 1998 ; 59 (Suppl 20) : 22-57.
18. TRANTER R et al. Prevalence and outcome of partial remission in depression. J Psychiatry Neurosci 2002 ; 27 (4) : 241-7.